Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

(FSE:24H) The company announced the closing of a €115 million licensing transaction with SERB. As of 30 September 2026, cash and cash equivalents amounted to 1,337.2 MSEK. The first commercial patient in Australia received a living-donor kidney transplant following treatment with Idefirix (Imlifidase). The company is headquartered in Lund, Sweden. The announcement highlights the successful completion of a significant licensing deal, a strong cash position at the end of the reporting period, and a milestone in the commercial use of Idefirix in Australia. The company continues to advance its commercial and financial objectives.